ClinicalTrials.gg
RecruitingNCT06595108A-BESTUpdated Nov 1, 2024

Atezolizumab and BEvacizumab With STereotactic Body Radiotherapy for Advanced Hepatocellular Carcinoma

An interventional study of Stereotactic body radiotherapy in Advanced Hepatocellular Carcinoma, Chemotherapy and Stereotactic Body Radiotherapy, sponsored by Yonsei University. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-11-01.

Sponsored by Yonsei University · Not applicable, Interventional, and Treatment

How we know · 2 judgments

From the registry’s dates

  • Started May 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
19 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Carcinoma, Hepatocellular by Yonsei University — 6 open to participants now, 6 under way, none of them phase 3. Carcinoma, Hepatocellular · Yonsei University.

Planned enrollment
9th of 11
33 · median 48
Started
2024
with 2 others
No phase
5 of 14
3 open now
Registered
11th of 14
by date

Among the 14 studies in Carcinoma, Hepatocellular by Yonsei University, this one is the 9th largest by planned enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2024, is one of 5 with no phase, and was the 11th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

6 of the 14 studies in Carcinoma, Hepatocellular by Yonsei University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 19 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Carcinoma, Hepatocellular by Yonsei University, or all of them as a file.
02

Study summary

To determine the efficacy and safety of atezolizumab-bevacizumab combination therapy plus stereotactic body radiotherapy(SBRT) in patients with advanced hepatocellular carcinoma, Subjects will start SBRT for one or more primary cancers and/or metastatic lesions and no more than 5 sites within two month before and after the start date of atezolizumab-bevacizumab combination therapy.

In this study, it is expected to improve the treatment response rate of atezolizumab-bevacizumab therapy, which is currently first-line chemotherapy but has a low treatment response rate.

Read the detailed description

The subjects with advanced hepatocellular carcinoma who are indicated for the first-line atezolizumab-bevacizumab combination therapy are the primary subjects, and if they voluntarily agree to the clinical trial after explanation of the clinical trial, they are included in the clinical trial. Subjects should begin SBRT(stereotactic body radiotherapy) to one or more but not more than five sites for primary cancer and/or metastatic lesions within two month before and after the start date of atezolizumab-bevacizumab combination therapy.

The followings are evaluation items for each visit.

Visit 1 (-6\~0 weeks) ± 7days *Screening

  • Informed consent form
  • Inclusion Criteria/ Exclusion Criteria
  • Medical history and physical examination
  • Staging via CT, MRI, PET-CT, etc. (PET-CT examination is not compulsory)
  • CBC, SMA, PT/aPTT, Tumor markers, Biomarkers
  • Stool microbiota NGS
  • QoL Questionnaire(EORTC-QLQ-C30 V3)

Visit 2 (0\~7 weeks) ± 7 days *During SBRT

  • Confirmation of adverse events
  • QoL Questionnaire(EORTC-QLQ-C30 V3)

Visit 3 (1\~8 weeks) *1 week after SBRT

  • Confirmation of adverse events
  • CBC, SMA, PT/aPTT, Tumor markers, Biomarkers
  • QoL Questionnaire(EORTC-QLQ-C30 V3)

Visit 4 (6\~9 weeks) ± 7 days *After 2 cycles of chemotherapy

  • Confirmation of adverse events
  • CBC, SMA, PT/aPTT, Tumor markers, Biomarkers
  • Stool microbiota NGS
  • QoL Questionnaire(EORTC-QLQ-C30 V3)

Visit: 5\~12 (3\~36 months) ± 2 weeks *Follow-up

  • Confirmation of adverse events
  • Evaluation of effectiveness* (Imaging tests, Tumor markers, CBC, SMA, PT/aPTT are performed according to the need)
  • QoL Questionnaire(EORTC-QLQ-C30 V3)
03

Conditions studied

  • Advanced Hepatocellular Carcinoma
  • Chemotherapy
  • Stereotactic Body Radiotherapy

Keywords

  • atezolizumab-bevacizumab
  • SBRT
04

Who can participate

Ages eligible
19 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 19 to 80 years old
  2. Liver function class A
  3. 0-1
  4. Patient clinically or diagnosed with hepatocellular carcinoma
  5. Advanced hepatocellular carcinoma that is inoperable
  6. Satisfies the dose limits for normal organs and lesions of an appropriate size to be included in the scope of radiotherapy.

Exclusion criteria

Exclusion Criteria:

  1. Have a history of other than hepatocellular carcinoma within the last 5 years (except for malignancies with little risk of or death, e.g., adequately treated cervical carcinoma in situ, non-melanoma skin cancer, localized prostate cancer, tubular carcinoma in situ, or stage 1 uterine cancer.)
  2. Subjects with a high probability of untreated gastric or esophageal varices or bleeding
  3. Serious uncontrolled medical comorbidities
  4. History of liver transplant surgery
  5. liver disease
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (estimated)

Study arms

  • Experimental
    Patients with advanced hepatocellular carcinoma

    Patients indicated for the first-line atezolizumab-bevacizumab combination therapy are the primary subjects, and those voluntarily agree to the clinical trial after explanation of the study, are enrolled in the study.

    Radiation: Stereotactic body radiotherapy

Interventions

  • RadiationStereotactic body radiotherapy

    Patients with advanced hepatocellular carcinoma who are indicated for the first-line atezolizumab-bevacizumab combination therapy are the primary subjects, and they should begin stereotactic radiotherapy to one or more but not more than five sites for primary cancer and/or metastatic lesions within two month before and after the start date of atezolizumab-bevacizumab combination therapy.

This study also gives AtezolizumabStudies of AtezolizumabAtezolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Progression-free survival at 6 month

    The primary endpoint is to improve 6-month progression-free survival rate in the treatment group compared to those existing literature. Progression-free survival and overall survival are evaluated using the Kaplan-Meier curve. Verified through one sample proportion test.

    Time frame: 6 months after registration

Secondary outcomes

  1. Overall survival

    Progression-free survival and overall survival are evaluated using the Kaplan-Meier curve. Verified through one sample proportion test.

    Time frame: 36 months after registration

  2. Objective response rate

    Objective response rate will be ratepresented as a proportion of the total.

    Time frame: 36 months after registration

  3. Adverse event (Toxicity)

    Toxicity will be evaluated using CTCAE version 5.0 and presented as a proportion of the total.

    Time frame: 36 months after registration

  4. Tumor marker response: AFP, PIVKA-II

    Tumor markers and biological markers are descriptive as statistics such as mean, standard deviation, and median for continuous data will be presented, and changes in values before and after treatment will be compared and evaluated using paired t-test or Wilcoxon signed rank test.

    Time frame: 36 months after registration

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Meng L, Xu J, Ye Y, Wang Y, Luo S, Gong X. The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients. Front Immunol. 2021 Sep 21;12:723609. doi: 10.3389/fimmu.2021.723609. eCollection 2021. PubMed 34621270 ↗
  • Demaria S, Golden EB, Formenti SC. Role of Local Radiation Therapy in Cancer Immunotherapy. JAMA Oncol. 2015 Dec;1(9):1325-32. doi: 10.1001/jamaoncol.2015.2756. PubMed 26270858 ↗
  • Demaria S, Guha C, Schoenfeld J, Morris Z, Monjazeb A, Sikora A, Crittenden M, Shiao S, Khleif S, Gupta S, Formenti SC, Vikram B, Coleman CN, Ahmed MM. Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose? J Immunother Cancer. 2021 Apr;9(4):e002038. doi: 10.1136/jitc-2020-002038. PubMed 33827904 ↗
  • Byun HK, Kim N, Park S, Seong J. Acute severe lymphopenia by radiotherapy is associated with reduced overall survival in hepatocellular carcinoma. Strahlenther Onkol. 2019 Nov;195(11):1007-1017. doi: 10.1007/s00066-019-01462-5. Epub 2019 Apr 15. PubMed 30989242 ↗
  • Theelen WSME, Peulen HMU, Lalezari F, van der Noort V, de Vries JF, Aerts JGJV, Dumoulin DW, Bahce I, Niemeijer AN, de Langen AJ, Monkhorst K, Baas P. Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019 Sep 1;5(9):1276-1282. doi: 10.1001/jamaoncol.2019.1478. PubMed 31294749 ↗
  • Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJ. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 Jun 1;36(16):1611-1618. doi: 10.1200/JCO.2017.76.2229. Epub 2018 Feb 13. PubMed 29437535 ↗
  • Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, Keall P, Lovelock M, Meeks S, Papiez L, Purdie T, Sadagopan R, Schell MC, Salter B, Schlesinger DJ, Shiu AS, Solberg T, Song DY, Stieber V, Timmerman R, Tome WA, Verellen D, Wang L, Yin FF. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010 Aug;37(8):4078-101. doi: 10.1118/1.3438081. Erratum In: Med Phys. 2012 Jan;39(1):563. Dosage error in article text. Med Phys. 2023 Jun;50(6):3885. doi: 10.1002/mp.16159. PubMed 20879569 ↗
  • Timmerman R. A Story of Hypofractionation and the Table on the Wall. Int J Radiat Oncol Biol Phys. 2022 Jan 1;112(1):4-21. doi: 10.1016/j.ijrobp.2021.09.027. No abstract available. PubMed 34919882 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Apr 2027, 34 months after the start.

Of 361 non-industry interventional studies with no phase under Carcinoma, Hepatocellular, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's planned 34 months is below that.

Counting every sponsor, half of 385 studies reached it within 47 months; a quarter within 23 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2024
First posted
Sep 19, 2024
StartActual
May 28, 2024
Primary completionEst.
Apr 25, 2027
CompletionEst.
Mar 27, 2028
Last update
Nov 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06595108
Lead sponsor
Yonsei University
Responsible party
Hwa Kyung Byun (Professor, Yonsei University) — Principal investigator
First posted
Sep 19, 2024
Start date
May 28, 2024
Primary completion
Apr 25, 2027 (estimated)
Completion
Mar 27, 2028 (estimated)
Last update
Nov 1, 2024

Study contacts

Hwakyung BYUN, Phd
Contact
hkbyun05@yuhs.ac
007981072098955
Hwakyung BYUN, Phd
principal investigator · Severance Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion